EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Modulation of the immune response of Balb/c mice against Leishmania major by imuvert



Modulation of the immune response of Balb/c mice against Leishmania major by imuvert



International Journal of Immunopharmacology 19(8): 443-449



This study investigated the effect of Imuvert, a biological response modifier derived from Serratia marcescens, on the progression of Leishmania major infection in Balb/c mice. A single 100 micrograms Imuvert injection was significantly protective in Balb/c mice when challenged 28 days later in the footpad with 5 x 10(5) stationary phase L. major promastigotes. Intraperitoneal (i.p.) and intravenous (i.v.) immunization of mice with heat-killed stationary phase L. major promastigotes significantly reduced lesion development following challenge with L. major promastigotes. Subcutaneous (s.c.) immunization had no protective effect. A single 100 micrograms Imuvert injection significantly reduced lesion development in s.c. immunized mice, but had a lesser effect in mice immunized by i.p. and i.v. routes. Balb/c mice receiving four Imuvert injections 14, 7, 2 and 1 day prior to footpad challenge with L. major promastigotes were not protected, but rather displayed significant exacerbation of infection. Our results suggest the possibility that Imuvert could be useful in stimulating a protective response against L. major when given along with s.c. vaccine, a realistic route for vaccinating humans in contrast to either i.v. or i.p. routes. Since the protective response in Balb/c mice against L. major is dependent on the stimulation of Th1 cells, it is suggested that the observed adjuvant effect of Imuvert given with s.c. vaccine perhaps is due to changes in immunological responses in such a direction.

(PDF emailed within 0-6 h: $19.90)

Accession: 009037684

Download citation: RISBibTeXText

PMID: 9568550

DOI: 10.1016/s0192-0561(97)00087-8



Related references

Treatment with cathepsin L inhibitor potentiates Th2-type immune response in Leishmania major-infected BALB/c mice. International Immunology 13(8): 975-982, 2001

Heat shock proteins enriched-promastigotes of Leishmania major inducing Th2 immune response in BALB/c mice. Iranian Biomedical Journal 16(4): 209-217, 2013

Evaluation of immune response against autoclaved Leishmania major incorporated into positively charged liposomes in Balb/c mice. Iranian Journal of Dermatology 10(1): 7, Ar37-Ar53, 2007

Leishmania major: immune response in BALB/c mice immunized with stress-inducible protein 1 encapsulated in liposomes. Experimental Parasitology 115(2): 127-134, 2006

Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice. Iranian Journal of Basic Medical Sciences 16(9): 965-972, 2013

Immune response and protection assay of recombinant major surface glycoprotein of Leishmania (rgp63) reconstituted with liposomes in BALB/c mice. Vaccine 24(29-30): 5708-5717, 2006

Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major mixed with BCG or Mycobacterium vaccae. Tropical Biomedicine: 1, 89-102, 2010

The role of liposome charge on immune response generated in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63). Experimental Parasitology 121(4): 362-369, 2009

Co-infection with Toxoplasma gondii switches the expected TH2 immune response into TH1, limiting inflammation and tissue parasitism in BALB/C mice infected with Leishmania major. Memorias do Instituto Oswaldo Cruz 93(SUPPL 2): 223-224, 1998

The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 25(32): 6107-6117, 2007

Coencapsulation of CpG oligodeoxynucleotides with recombinant Leishmania major stress-inducible protein 1 in liposome enhances immune response and protection against leishmaniasis in immunized BALB/c mice. Clinical and Vaccine Immunology 15(4): 668-674, 2008

Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids and Surfaces. B, Biointerfaces 74(1): 37-44, 2009

Immune response to Leishmania (Leishmania) chagasi infection is reduced in malnourished BALB/c mice. Memorias do Instituto Oswaldo Cruz 105(6): 811-817, 2011

Immune response of BALB/c mice against an experimental vaccine of Alum precipitated autoclaved Leishmania major (Alum-ALM) mixed with BCG or Mycobacterium vaccae. Tropical Biomedicine 27(1): 89-102, 2011